Alector discontinues phase 2 Alzheimer's trial after futility analysis

April 29, 2026 4:05 PM

Alector Inc. (NASDAQ: ALEC) announced it will discontinue its Phase 2 PROGRESS-AD trial of nivisnebart in early Alzheimer's disease following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found